<DOC>
	<DOCNO>NCT00543231</DOCNO>
	<brief_summary>GenasenseÂ® currently administer subject clinical study multiple-day continuous intravenous infusion . Subjects treat outpatient basis carry pump delivers drug peripheral central intravenous line . The route administration limit convenience treatment , catheter-related complication report . This study design evaluate pharmacokinetics safety G3139 administer subcutaneuous injection .</brief_summary>
	<brief_title>A Phase I Study G3139 Subcutaneous Solid Tumors</brief_title>
	<detailed_description />
	<criteria>A Confirmed diagnosis solid tumor malignancy , include lymphoma , fail standard therapy standard therapy available . Patients history brain metastasis eligible evidence cerebral edema treatment steroid . Adequate organ function determine &lt; 7 day prior start study medication Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 At least 3 week recovery effect major prior surgery therapy include radiation therapy , immunotherapy , cytokine , biological , vaccine chemotherapy Significant medical diesese History leptomeningeal disease Coexisting condition would require subject continue therapy treatment phase study drug know alter renal function . Use investigational drug within 3 week prior start study medication Known hypersensitivity phosphorothioatecontaining oligonucleotides Pregnancy/Lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2005</verification_date>
	<keyword>ECOG</keyword>
	<keyword>MRT</keyword>
	<keyword>NCI CTC</keyword>
	<keyword>SAE</keyword>
	<keyword>Short Intravenous Infusion Patients Solid Tumors</keyword>
</DOC>